Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. European Commission. European cancer information system. https://ecis.jrc.ec.europa.eu
  Google Scholar
• 3. Sociedad Española Oncología Médica. Las cifras del cáncer en España (2022). https://seom.org/prensa/el-cancer-en-cifras
  Google Scholar
• 4. Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370(10), 932–942 (2014).
  Medline CASGoogle Scholar
• 5. Weiner AB, Nettey OS, Morgans AK. Management of metastatic hormone-sensitive prostate cancer (mHSPC): an evolving treatment paradigm. Curr. Treat. Options Oncol. 20(9), 69 (2019).
  MedlineGoogle Scholar
• 6. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43(2), 209–223 (1941).
  CASGoogle Scholar
• 7. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017).
  Medline CASGoogle Scholar
• 8. Armstrong AJ, Lin P, Tombal B et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur. Urol. 78(3), 347–357 (2020).
  Medline CASGoogle Scholar
• 9. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
  Medline CASGoogle Scholar
• 10. Chi KN, Chowdhury S, Bjartell A et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39(20), 2294–2303 (2021).
  Medline CASGoogle Scholar
• 11. Gravis G, Fizazi K, Joly F et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14(2), 149–158 (2013).
  Medline CASGoogle Scholar
• 12. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
  Medline CASGoogle Scholar
• 13. Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
  Medline CASGoogle Scholar
• 14. Fizazi K, Foulon S et al. LBA5_PR – a phase III trial with a 2×2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. Ann. Oncol. 32(Suppl. 5), S1283–S1346 (2021).
  Google Scholar
• 15. Burdett S, Boevé LM, Ingleby FC et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur. Urol. 76(1), 115–124 (2019).
  MedlineGoogle Scholar
• 16. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
  Medline CASGoogle Scholar
• 17. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010). •• Pivotal clinical trial demonstrating the benefit of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with docetaxel; it led to approval of cabazitaxel by the US FDA in 2010.
  Medline CASGoogle Scholar
• 18. de Wit R, de Bono J, Sternberg CN et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381(26), 2506–2518 (2019). • Important clinical trial that clarifies the best sequence of treatments in mCRPC, with cabazitaxel having a relevant role in therapeutic management.
  Medline CASGoogle Scholar
• 19. Jabir RS, Naidu R, Annuar MABA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 13(16), 1979–1988 (2012). • Review addressing relevant information on genetic variations of transporters that affect the pharmacokinetics and toxicity of taxanes.
  CASGoogle Scholar
• 20. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9(10), 790–803 (2010).
  Medline CASGoogle Scholar
• 21. Rodríguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 11(5), 621–623 (2010).
  CASGoogle Scholar
• 22. Leandro-García LJ, Leskelä S, Inglada-Pérez L et al. Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res. 72(18), 4744 (2012).
  Medline CASGoogle Scholar
• 23. Schwartz LH, Litière S, de Vries E et al. RECIST 1.1 – update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132–137 (2016).
  MedlineGoogle Scholar
• 24. Melzack R, Raja Srinivasa N. The McGill Pain Questionnaire: from description to measurement. Anesthesiology 103(1), 199–202 (2005).
  MedlineGoogle Scholar
• 25. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE v5.0) (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
  Google Scholar
• 26. Garrigós C, Espinosa M, Salinas A et al. Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. Oncotarget 8(63), 106551–106564 (2017).
  MedlineGoogle Scholar
• 27. Duran I, Hagen C, Arranz JÁ et al. SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics 17(5), 463–471 (2016). •• Pharmacogenomic study where the impact of single-nucleotide polymorphisms (SNPs) in the same genes as in the current study is observed but in patients with urothelial cancer treated with cabazitaxel.
  CASGoogle Scholar
• 28. Belderbos BPS, de With M, Singh RK et al. The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 85(3), 547–553 (2020). •• First published prospective study in mCRPC evaluating the effect of SNPs of genes associated with the pharmacokinetics of cabazitaxel on its efficacy and toxicity
  Medline CASGoogle Scholar
• 29. Varnai R, Koskinen LM, Mäntylä LE, Szabo I, FitzGerald LM, Sipeky C. Pharmacogenomic biomarkers in docetaxel treatment of prostate cancer: from discovery to implementation. Genes (Basel) 10(8), 599 (2019). • Provides an overview and discusses the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer.
  CASGoogle Scholar
• 30. Galsky M, Dritselis A, Kirkpatrick P et al. Cabazitaxel. Nat. Rev. Drug Discov. 9, 677–678 (2010).
  Medline CASGoogle Scholar